Compare HROW & XHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HROW | XHR |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | 373 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | N/A | 2014 |
| Metric | HROW | XHR |
|---|---|---|
| Price | $38.00 | $21.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $69.86 | $15.67 |
| AVG Volume (30 Days) | 614.5K | ★ 628.5K |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 3.48% |
| EPS Growth | N/A | ★ 326.67 |
| EPS | N/A | ★ 0.21 |
| Revenue | N/A | ★ $1,078,500,000.00 |
| Revenue This Year | $31.62 | $3.94 |
| Revenue Next Year | $50.77 | $2.68 |
| P/E Ratio | ★ N/A | $102.33 |
| Revenue Growth | N/A | ★ 3.80 |
| 52 Week Low | $28.54 | $11.75 |
| 52 Week High | $54.98 | $21.66 |
| Indicator | HROW | XHR |
|---|---|---|
| Relative Strength Index (RSI) | 39.38 | 69.87 |
| Support Level | $37.81 | $14.26 |
| Resistance Level | $41.94 | N/A |
| Average True Range (ATR) | 2.28 | 0.45 |
| MACD | -0.87 | 0.02 |
| Stochastic Oscillator | 6.61 | 92.00 |
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Xenia Hotels & Resorts Inc is a real estate investment trust that invests in premium full-service, lifestyle, and urban upscale hotels and resorts across the United States. The company owns and pursues hotels in the upscale, upper upscale, and luxury segments that are affiliated with various brands. Its hotels are operated by Marriott, along with Hilton, Hyatt, Starwood, Kimpton, Aston, Fairmont, and Loews. The firm's properties are located in various regions across the U.S.: the South Atlantic, West South Central, Pacific, Mountain, and other regions. Xenia's revenue is divided between the sale of rooms, food and beverages, and other sources.